Indications: Papliovax is indicated for females aged 9–45 years to prevent diseases caused by oncogenic HPV types 16 and/or 18, including:

Cervical cancer
Cervical intraepithelial neoplasia (CIN) Grade 2/3 and adenocarcinoma in situ (AIS)
CIN Grade 1 and persistent HPV 16/18 infections

Vaccination is recommended as early as possible, ideally before sexual debut, for maximum benefit.

Composition (per 0.5 ml dose):

Recombinant HPV type 16 L1 protein: 40 µg
Recombinant HPV type 18 L1 protein: 20 µg Formulated with aluminum hydroxide adjuvant, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, polysorbate 80, and water for injection.

Description: Papliowax is a suspension for injection in a prefilled syringe. After storage, a fine white deposit with clear supernatant may appear; thorough shaking produces a homogeneous suspension. Contains no preservatives.

Dosage & Administration:

Standard schedule: 3 doses of 0.5 ml intramuscularly at 0, 1, and 6 months.
Alternative schedule (ages 9–14): 2 doses at 0 and 6 months (interval ≥5 months).
Preferred injection site: deltoid muscle.
Do not administer subcutaneously, intravenously, or intradermally.
Inspect syringe before use; discard if abnormal appearance or damaged packaging.
Shake well before injection.

Co‑administration: No data on concomitant use with other vaccines. Do not mix in the same syringe. Immunosuppressive therapies (radiation, cytotoxic drugs, corticosteroids) may reduce immune response. Avoid immunoglobulin or blood products within 3 months prior to vaccination.

Interactions: Immunosuppressive therapy may reduce vaccine efficacy.

Contraindications:

Hypersensitivity to active substances or excipients
Individuals developing hypersensitivity symptoms after a previous dose

Side Effects:

Local: Pain, swelling, erythema, pruritus at injection site (very common).
Systemic: Fever, headache, fatigue, myalgia, arthralgia, GI symptoms (common).
Occasional: Hypersensitivity, rash, dizziness, allergic dermatitis. Most reactions are mild to moderate.

Pregnancy & Lactation:

Pregnancy: Limited data; accidental vaccination has not shown adverse outcomes, but vaccination should be postponed until after pregnancy.
Lactation: No specific studies; use with caution as many drugs can be secreted in breast milk.

Precautions & Warnings:

Vaccination does not replace routine cervical cancer screening.
Medical history should be reviewed before vaccination.
Syncope (fainting) may occur, especially in adolescents; observe for at least 30 minutes post‑vaccination.
Emergency measures should be available in case of allergic reactions.